A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis

Data from a completed phase 2/3 trial, MOL-PAP-002, suggested that molgramostim, an inhaled form of the recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF), improves lung pathology, pathophysiology, and health status in subjects with aPAP in a dose-frequency dependent fashion. The present confirmatory phase 3 trial will be conducted to further investigate the efficacy and safety of molgramostim in subjects with aPAP.